Family History
Introduction
Background
Family history refers to the comprehensive record of medical information about an individual's biological relatives, spanning multiple generations. It serves as a foundational tool in healthcare and genetics, offering critical insights into inherited predispositions to various diseases and traits. By examining the health patterns within a family, healthcare providers can identify potential risks and understand an individual's susceptibility to certain conditions, even before symptoms appear.
Biological Basis
The biological underpinning of family history is rooted in the inheritance of genetic material. Close relatives share a significant portion of their DNA, meaning that genetic variants, including single nucleotide polymorphisms (SNPs), can be passed down, influencing shared health outcomes. Research employs advanced methods, such as SNP-based heritability estimation using models like the LD- and MAF-stratified genomic relatedness matrix (GRM) restricted maximum likelihood (GREML-LDMS), to quantify the genetic contribution to complex traits. [1] Studies also delve into the role of rare variants and high-confidence loss-of-function (LOF) variants, which can profoundly impact gene function and disease risk. [2] The genetic architecture of populations, influenced by demographic history and natural selection, dictates how traits are inherited and expressed across family lines. [3] Polygenic risk scores (PGS) are increasingly used to assess an individual's cumulative genetic predisposition to diseases by integrating the effects of many genetic variants. [4]
Clinical Relevance
Family history is an indispensable component of clinical risk assessment, guiding tailored screening, preventive measures, and personalized treatment strategies. For example, a documented family history of Alzheimer's disease is a recognized risk factor, prompting heightened vigilance and potential early interventions. [5] Similarly, a family history of coronary artery disease (CAD) or familial lung cancer can inform clinical decisions, such as recommending specific diagnostic tests or lifestyle modifications. [6] Healthcare professionals integrate family history with other clinical data to construct comprehensive health profiles, enabling the identification of individuals who may benefit from targeted genetic testing, counseling, or enhanced surveillance. [7]
Social Importance
Beyond its biological and clinical utility, family history holds significant social importance. It empowers individuals to make informed health decisions, adopt proactive lifestyle changes, and facilitates crucial intergenerational dialogue about health matters. Shared family health patterns can also contribute to the design of community health initiatives and public health strategies. The collection and interpretation of family health information necessitate careful consideration of privacy, data sharing ethics, and the role of genetic counseling in supporting families as they navigate complex health information. Research acknowledges the social context of individuals, sometimes considering factors like the presence of family outside the household, when studying health-related behaviors [8] and analyzes relationships such as parent-offspring and full sibling pairs to understand genetic inheritance within family structures. [3]
Methodological and Statistical Considerations
The statistical power and robustness of genetic association studies are critically influenced by their design and execution. Simulations often rely on subsets of individuals, for example, 50,000 samples from a larger cohort, representing a trade-off between computational feasibility and the ability to detect subtle genetic associations. This choice can lead to challenges in identifying variants with small effect sizes or for traits with very low prevalence, where test statistics may be deflated and statistical power is insufficient to robustly detect associations. [9]
Furthermore, the accurate estimation of genetic effects and their replication across studies can be hampered by several factors. When individual-level data is unavailable, researchers must often rely on p-value-based meta-analyses to indirectly estimate pooled effect sizes, and inaccuracies in this process can significantly impact subsequent analyses. [10] Differences in the choice of GWAS methods or the specific affinity-based assaying approaches used to quantify biological markers can also lead to varying measurements and inconsistent replication rates across different cohorts, complicating the synthesis of findings. [10]
Population and Phenotype Heterogeneity
The generalizability of genetic findings is often constrained by the ancestral composition of the study populations. Many large-scale genetic studies predominantly feature individuals of European descent, such as those within the UK Biobank, which can limit the applicability of discovered associations and polygenic scores to other ancestral groups. [9] Population-specific genetic architectures and allele frequencies mean that findings from one ancestry may not translate directly, potentially leading to biased results if diverse populations are underrepresented in imputation panels or if population-specific variants are overlooked. [11] While some genetic effects show directional concordance across ancestries for quantitative traits, this consistency is often weaker for binary traits, underscoring the need for more ethnically diverse cohorts to ensure broad relevance and predictive accuracy. [12]
Challenges also arise from the definition and measurement of phenotypes. When "family history" is self-reported, it introduces a potential for recall bias or inaccurate reporting, which can diminish the precision of the outcome variable used in genetic association studies. [5] Beyond self-report, the use of different methodologies, such as various affinity-based assays for quantifying circulating proteins, can yield measurements that vary significantly for the same biological markers, often with only moderate correlations between them. [10] Such inconsistencies in phenotypic measurement directly impact the ability to accurately detect and replicate genetic signals, making robust cross-cohort comparisons difficult and potentially obscuring true genetic associations.
Confounding and Unaccounted Genetic Effects
Despite rigorous efforts to control for confounding factors like population stratification and genetic relatedness through methods such as principal component analysis, residual environmental or shared familial effects can still influence genetic association studies. [9] These unmeasured or incompletely adjusted environmental factors can mimic genetic signals or modulate their expression, thereby complicating the accurate disentanglement of genetic contributions from environmental influences. The complexity of real-world environmental interactions often exceeds what can be fully captured and adjusted for in statistical models, potentially leading to misleading associations or an underestimation of true genetic effects. [9]
Furthermore, a significant portion of the heritability for complex traits often remains unexplained by identified genetic variants, a phenomenon referred to as "missing heritability." This suggests that current genetic association studies may not fully capture the contributions of rare variants, intricate gene-gene interactions, or epigenetic factors. [2] Additionally, the limited ability to scale genetic explorations across cohorts that utilize different proteomic platforms, due to assay differences, represents a substantial knowledge gap. This hinders a comprehensive and integrated understanding of the full genetic architecture underlying various traits, necessitating further large-scale comparative research to bridge these gaps. [10]
Variants
Genetic variations play a crucial role in determining an individual's susceptibility to various conditions, influencing gene activity and protein function. Understanding these variants, especially in the context of family history, can provide insights into inherited risk patterns and potential health trajectories.
The _APOE_ gene, located on chromosome 19, is a central player in lipid metabolism and is the strongest known genetic risk factor for Alzheimer's disease (AD). Variants rs7412 (epsilon 2 allele) and rs429358 (epsilon 4 allele) are critical determinants of _APOE_ genotype, with epsilon 4 increasing AD risk and epsilon 2 offering some protection. [13] These variants have been identified as having likely deleterious impacts on gene function, strongly associating with AD risk and influencing a large number of proteins in cerebrospinal fluid. [4] The _APOE_ / _TOMM40_ locus, which includes these variants, is a gene-dense region where many lead SNPs associated with parental AD status are concentrated. [5] Family history of AD is therefore significantly influenced by the inheritance of these _APOE_ alleles, highlighting their importance in assessing familial risk. The region encompassing _APOE_ and _APOC1_, represented by variants like rs1065853, also plays a role in lipid processing, with _APOC1_ influencing _APOE_'s function in cholesterol transport and potentially modulating AD risk.
Beyond neurodegeneration, several variants are implicated in metabolic and cardiovascular health. Variants such as rs7903146 and rs34872471 in the _TCF7L2_ gene are widely recognized for their strong association with type 2 diabetes, affecting insulin secretion and glucose homeostasis. [14] Similarly, variations in the _LPA_ gene, including rs10455872 and rs55730499, are associated with elevated levels of lipoprotein(a), a known risk factor for cardiovascular diseases like atherosclerosis and myocardial infarction. [15] The _CELSR2_ gene, with variants like rs12740374 and rs7528419, is involved in cell adhesion and planar cell polarity, and its locus is frequently associated with lipid levels and cardiovascular disease risk, often alongside _PSRC1_ and _SORT1_. Variants within the _SMARCA4_ - _LDLR_ region, such as rs73015024, rs138294113, and rs142130958, can impact cholesterol metabolism through _LDLR_ (Low-Density Lipoprotein Receptor), which is crucial for clearing LDL cholesterol from the bloodstream, thereby influencing familial hypercholesterolemia and related cardiovascular risks.
Other variants contribute to a range of complex traits. The _CHRNA5_ gene, with variants like rs55781567, encodes a subunit of nicotinic acetylcholine receptors and is strongly linked to nicotine dependence and lung cancer risk, demonstrating how genetic predispositions can influence behavioral traits and related health outcomes. The _CDKN2B-AS1_ gene, an antisense RNA, is involved in cell cycle regulation and is frequently associated with glaucoma, cardiovascular disease, and type 2 diabetes through variants like rs9644862, rs10738608, and rs10965247, often acting as a long non-coding RNA to regulate expression of neighboring _CDKN2A_ and _CDKN2B_ tumor suppressor genes. Variants in regions like _PSMA4_ - CHRNA5, such as *rs72740955*, and in genes like CASC19andPCAT1`, exemplified by rs188140481, are also emerging as important in various disease contexts, including certain cancers and other complex disorders, where their influence on gene expression and cellular pathways can contribute to inherited disease susceptibility.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs7903146 rs34872471 |
TCF7L2 | insulin measurement clinical laboratory measurement, glucose measurement body mass index type 2 diabetes mellitus type 2 diabetes mellitus, metabolic syndrome |
| rs10455872 rs55730499 |
LPA | myocardial infarction lipoprotein-associated phospholipase A(2) measurement response to statin lipoprotein A measurement parental longevity |
| rs7412 rs429358 |
APOE | low density lipoprotein cholesterol measurement clinical and behavioural ideal cardiovascular health total cholesterol measurement reticulocyte count lipid measurement |
| rs73015024 rs138294113 rs142130958 |
SMARCA4 - LDLR | total cholesterol measurement low density lipoprotein cholesterol measurement phospholipids in medium LDL measurement phospholipids in VLDL measurement blood VLDL cholesterol amount |
| rs12740374 rs7528419 |
CELSR2 | low density lipoprotein cholesterol measurement lipoprotein-associated phospholipase A(2) measurement coronary artery disease body height total cholesterol measurement |
| rs1065853 | APOE - APOC1 | low density lipoprotein cholesterol measurement total cholesterol measurement free cholesterol measurement, low density lipoprotein cholesterol measurement protein measurement mitochondrial DNA measurement |
| rs55781567 | CHRNA5 | forced expiratory volume, response to bronchodilator FEV/FVC ratio, response to bronchodilator lung carcinoma upper aerodigestive tract neoplasm urate measurement |
| rs9644862 rs10738608 rs10965247 |
CDKN2B-AS1 | carotid plaque build family history |
| rs72740955 | PSMA4 - CHRNA5 | forced expiratory volume, response to bronchodilator FEV/FVC ratio, response to bronchodilator smoking cessation cigarettes per day measurement pack-years measurement |
| rs188140481 | CASC19, PCAT1 | prostate carcinoma prostate cancer family history |
Conceptualizing Family History as a Trait
Family history, in a clinical and research context, refers to the documented presence of specific diseases or traits within an individual's biological relatives. This concept serves as a crucial proxy for understanding genetic predispositions and the influence of shared environmental factors on health outcomes. [16] Operationally, it is often defined by direct patient reports identifying affected family members, as seen in studies where individuals indicate a "family history of CAD" [7] or "family history of Alzheimer's disease". [5] Such definitions enable the categorization of individuals into groups, such as those with a "positive family history" versus those without, which is fundamental for subsequent analyses and risk assessments.
The measurement approach for family history typically involves collecting patient medical records and confirming conditions through medication intake or physician diagnoses, particularly for complex traits like Type 2 Diabetes Mellitus (T2DM), hypertension, and hyperlipidemia. [7] This data collection can extend to specific disease outcomes, such as severe coronary artery stenosis, where the presence of the condition in relatives is recorded. The "HERITAGE family study" exemplifies a research design that leverages family-based data to investigate various health parameters, underscoring the utility of family history in comprehensive health assessments. [1]
Clinical and Epidemiological Significance
Family history is a critical component in assessing an individual's risk for various complex diseases, serving as a powerful, albeit broad, diagnostic criterion. Its presence is often significantly associated with disease phenotypes, as demonstrated by studies showing a strong correlation between a positive family history and conditions like coronary artery disease (CAD), with a significant p-value and an odds ratio (OR) indicating increased risk. [7] This association extends to influencing the age of disease onset; for instance, a trend of decreasing mean age at diagnosis has been observed in individuals with a positive family history, particularly when combined with factors like consanguinity. [7]
In epidemiological classification systems, family history allows for the stratification of populations into risk categories. For instance, in populations with high rates of consanguinity, the combined effect of family history and relatedness can reveal distinct trends in disease presentation, highlighting its relevance in understanding population-specific health dynamics. [7] While family history itself is a categorical variable (present/absent or positive/negative), its impact often correlates dimensionally with disease severity or earlier onset, offering insights beyond a simple binary classification.
Research Applications and Genetic Architecture
In genetic research, family history is frequently utilized as a phenotype in genome-wide association studies (GWAS) to identify genetic susceptibility alleles associated with various conditions. [5] This approach, sometimes termed "case-control association mapping by proxy," uses reported family history as an indicator of genetic burden, especially for complex diseases. [16] Such studies aim to uncover the underlying genetic architecture by linking specific genetic variants to the likelihood of having affected relatives.
The scientific significance of family history in genetics is profound, as it provides an initial framework for identifying individuals who may carry genetic variants that increase disease risk. While not a direct biomarker, family history acts as a clinical criterion that guides further genetic investigation. The aggregation of diseases within families can also reflect shared genetic background and environmental exposures, making it an invaluable tool for understanding disease etiology and informing personalized medicine approaches.
Risk Assessment and Early Detection
Family history is a fundamental tool in clinical practice for identifying individuals at an elevated risk for various health conditions, enabling targeted screening and personalized prevention strategies. For example, a positive family history of coronary artery disease (CAD) is significantly associated with an increased likelihood of developing the disease, with individuals having such a history demonstrating 1.4 times higher odds of being affected . These studies often employ proxy-phenotyping, leveraging family history information to infer genetic associations for diseases, thereby expanding the scope of case-control association mapping in diverse populations. [16] Such approaches allow for the identification of numerous genomic risk loci and functional pathways associated with disease susceptibility, providing insights into prevalence patterns and potential temporal trends across broad demographic groups. [4]
Further longitudinal investigations, such as those within the NHLBI TOPMed Program, have sequenced tens of thousands of diverse genomes, contributing to a comprehensive understanding of genetic influences on the plasma proteome and its link to cardiovascular disease. [17] These studies typically involve rigorous genetic quality control, including filtering variants based on imputation quality, minor allele count, and Hardy-Weinberg Equilibrium, as well as accounting for ancestry using principal components analysis. [5] The careful adjustment for covariates like age, sex, and duration between blood draw and processing ensures that identified associations are robust and representative of population-level genetic effects.
Cross-Population Genetic Diversity and Health Disparities
Population studies frequently highlight significant genetic diversity and variations in disease susceptibility across different ancestral and geographic groups. Research in African American populations, for instance, has identified numerous protein quantitative trait loci (pQTLs) associated with kidney disease attributed to hypertension, underscoring the importance of population-specific genetic architectures in understanding health disparities. [18] Similarly, whole genome sequence analysis in Black adults has provided novel insights into cardiovascular disease by examining the plasma proteome, building upon cohorts like the Jackson Heart Study which specifically investigates cardiovascular risk in African Americans. [1]
Unique population histories and selective pressures also profoundly shape genetic architecture, as exemplified by studies in the Greenlandic population. Research in Greenland has revealed how demography, structure, and selection influence genetic variations, identifying specific high-impact recessive variants for type 2 diabetes and selective sweeps on genes like CPT1A. [19] These studies often differentiate between genetically inferred ancestry categories and self-identified labels to accurately capture the historical and contemporary effects of demography on disease genetics, further demonstrating the need for diverse population representation in genetic research. Comparisons involving multi-ancestry cohorts, including European, East Asian, American Hispanic/Latin, and African American groups, are also crucial for identifying host genetic factors influencing traits like gut microbiome composition, revealing both shared and population-specific effects. [20]
Epidemiological Associations and Methodological Rigor
Epidemiological studies routinely investigate the prevalence patterns and incidence rates of diseases, correlating them with various demographic and socioeconomic factors. For instance, in the Lebanese population, studies on severe coronary artery stenosis have examined epidemiological factors such as smoking status, diagnosis of type 2 diabetes mellitus, hypertension, hyperlipidemia, and the impact of consanguinity. [7] These investigations often collect detailed socio-demographic backgrounds and clinical data to understand the interplay between genetic predispositions and environmental exposures, providing a comprehensive view of disease etiology at a population level.
The methodological rigor of these studies is paramount for ensuring the representativeness and generalizability of findings. Common practices include the careful recruitment of participants, often from population registries, and stringent quality control of genomic data to exclude variants with poor imputation quality, low minor allele counts, or deviations from Hardy-Weinberg Equilibrium. [21] Additionally, researchers often remove closely related individuals to avoid confounding and use principal component analysis to account for population structure and ancestry, ensuring that observed associations are not artifacts of population stratification. [21] These meticulous study designs are crucial for drawing accurate conclusions about disease associations and their broader implications for public health.
Privacy, Data Governance, and Informed Consent
The collection and analysis of genetic information, particularly as it relates to family history, raise significant ethical concerns regarding individual privacy and the appropriate governance of sensitive data. Genetic data is uniquely identifiable and can reveal information not only about an individual but also about their biological relatives, even without their explicit consent or knowledge. The use of identity-by-descent (IBD) analysis, for instance, can determine genetic relatedness among samples, potentially identifying family members and uncovering unexpected relationships [22] This inherent interconnectedness necessitates stringent privacy protocols and robust data protection measures to prevent unauthorized access or misuse. Furthermore, obtaining truly informed consent is complex, as individuals must understand the broad implications of sharing their genetic data, including potential future uses and the impact on family members. Policies must clearly define data ownership, access rights, and the conditions under which genetic information can be shared or linked to other datasets, ensuring that individuals retain control over their genetic legacy.
Societal Impact and Discrimination Risks
Genetic insights derived from family history can carry profound societal implications, including the risk of discrimination and social stigma. Knowledge of genetic predispositions to certain diseases, even if probabilistic, can lead to unfair treatment in areas such as employment, insurance, or social interactions. Individuals or entire families might face stigma if they are identified as carriers for specific conditions or if their genetic profile is perceived negatively. Moreover, genetic information can influence deeply personal reproductive choices, presenting ethical dilemmas for prospective parents regarding screening, family planning, and the moral status of embryos. The potential for such data to exacerbate existing social inequalities or create new forms of discrimination underscores the critical need for legal protections and public education to combat misconceptions and ensure equitable treatment for all individuals, regardless of their genetic makeup.
Equity in Research and Healthcare Access
The development and application of genetic technologies based on family history must be approached with a strong commitment to health equity and justice, addressing potential disparities in research and access to care. Research studies that restrict participation based on ancestry, such as the exclusion of individuals of "non-European ancestry" in some cohorts, can lead to a significant bias in genetic databases [22] This narrow focus can limit the generalizability of findings, perpetuate health disparities by failing to identify genetic risk factors or therapeutic targets relevant to diverse populations, and ultimately hinder the development of inclusive healthcare solutions. Ensuring equitable access to genetic testing and counseling is also paramount, as socioeconomic factors, cultural considerations, and resource allocation can create barriers for vulnerable populations. A global health perspective is essential to ensure that the benefits of genetic research are shared broadly and that ethical guidelines and clinical practices are developed to serve all communities, promoting health equity rather than widening existing gaps.
Frequently Asked Questions About Family History
These questions address the most important and specific aspects of family history based on current genetic research.
1. My family has a lot of heart disease; am I doomed to get it?
No, you're not necessarily "doomed," but you do have an increased predisposition due to shared genetic material. Family history is a recognized risk factor, guiding doctors to recommend tailored screening and preventive measures for you. Embracing a healthy lifestyle can significantly mitigate these risks, empowering you to make informed decisions.
2. Can a healthy lifestyle really beat my family's bad health history?
Yes, a healthy lifestyle can significantly influence your health outcomes even with a genetic predisposition. Family history helps identify potential risks, but tailored screening, preventive measures, and proactive lifestyle changes are crucial. This knowledge empowers you to make informed decisions to manage your health effectively.
3. Why does my doctor ask so much about my family's health history?
Your doctor uses your family's health history as a foundational tool for clinical risk assessment. It offers critical insights into your potential inherited predispositions to various diseases. This information helps guide personalized screening, preventive measures, and treatment strategies, ensuring you receive the most relevant care.
4. I'm not European; does my ancestry change my family health risks?
Yes, your ancestral background can influence how family health risks apply to you. Many large-scale genetic studies predominantly feature individuals of European descent, meaning findings may not translate directly to other ancestral groups. Population-specific genetic architectures and allele frequencies can differ, highlighting the importance of diverse research.
5. My grandma had Alzheimer's; does that mean I'll get it?
A documented family history of Alzheimer's disease is a recognized risk factor, indicating an increased predisposition for you. This knowledge prompts heightened vigilance and potential early interventions. It's important to discuss this with your doctor to understand your specific risk and any recommended steps.
6. My sibling is healthy, but I'm not; why are we so different?
Even though you share a significant portion of your DNA with your sibling, you don't inherit identical combinations of genetic variants. Your unique genetic predispositions, coupled with individual lifestyle and environmental factors, can lead to different health outcomes. Polygenic risk scores, for example, assess each individual's cumulative genetic risk.
7. Is getting a DNA test useful for understanding my future health?
Family history can help determine if you would benefit from targeted genetic testing. Such tests can offer insights into your genetic predisposition to certain diseases by identifying specific genetic variants. However, interpreting this complex information often requires guidance from genetic counseling to understand the implications for your health.
8. Does knowing my family's health history just make me more anxious?
While it's understandable to feel anxious, knowing your family's health history can actually empower you. It enables you to make informed health decisions, adopt proactive lifestyle changes, and engage in crucial intergenerational dialogue about health. Genetic counseling can also provide support in navigating this complex information and managing any concerns.
9. Does where my family comes from change my disease risk?
Yes, it can. The genetic architecture of populations is influenced by demographic history and natural selection, which dictates how traits are inherited. This means your ancestral background can affect your specific genetic predispositions and disease risk, making it important context for your health profile.
10. Why does my doctor ask about my distant relatives' health?
Doctors collect family history spanning multiple generations because it offers comprehensive insights into inherited predispositions. Even distant relatives share some genetic material, and patterns across extended family lines can reveal risks for conditions like familial lung cancer or coronary artery disease that might not be apparent from immediate family alone.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Katz, D. H. et al. "Whole Genome Sequence Analysis of the Plasma Proteome in Black Adults Provides Novel Insights Into Cardiovascular Disease." Circulation, vol. 144, no. 23, 2021, pp. 1880–1892.
[2] Zhang, Y. R., et al. "Whole exome sequencing analyses identified novel genes for Alzheimer's disease and related dementia." Alzheimers & Dementia, 2024.
[3] Staeger, F. F. et al. "Genetic architecture in Greenland is shaped by demography, structure and selection." Nature, vol. 627, no. 8005, 2024, pp. 815–824.
[4] Jansen IE, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. Nat Genet. 2019.
[5] Marioni RE, et al. GWAS on family history of Alzheimer's disease. Transl Psychiatry. 2017.
[6] Byun, J., et al. "Genome-Wide Association Study of Familial Lung Cancer." Carcinogenesis, 2018.
[7] Wakim, V. et al. "New susceptibility alleles associated with severe coronary artery stenosis in the Lebanese population." BMC Med Genomics, vol. 14, no. 1, 2021, p. 86.
[8] Bralten, J., et al. "Genetic underpinnings of sociability in the general population." Neuropsychopharmacology, 2021.
[9] Loya, Hila. "A scalable variational inference approach for increased mixed-model association power." Nat Genet, vol. 57, Feb. 2025, pp. 461–468.
[10] Konieczny, Marcin J., et al. "The genomic architecture of circulating cytokine levels points to drug targets for immune-related diseases." Commun Biol, vol. 7, 2024, p. 1095.
[11] Thareja, G., et al. "Differences and commonalities in the genetic architecture of protein quantitative trait loci in European and Arab populations." Human Molecular Genetics, 2023.
[12] Backman, Joshua D., et al. "Exome sequencing and analysis of 454,787 UK Biobank participants." Nature, vol. 599, 25 Nov. 2021, pp. 631.
[13] Western D, et al. Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer's disease. Nat Genet. 2023.
[14] Suhre K, et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun. 2017.
[15] Reilly MP, et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet. 2011.
[16] Liu, J. Z. et al. "Case-control association mapping by proxy using family history of 363 disease." Nat Genet, vol. 49, no. 3, 2017, pp. 325–331.
[17] Taliun, D. et al. "Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program." Nature, vol. 590, no. 7845, 2021, pp. 290–299.
[18] Surapaneni, A. et al. "Identification of 969 protein quantitative trait loci in an African American population with kidney disease attributed to hypertension." Kidney Int, vol. 102, no. 5, 2022, pp. 1167–1177.
[19] Clemente, F. J. et al. "A selective sweep on a deleterious mutation in CPT1A in Arctic populations." Am J Hum Genet, vol. 95, no. 5, 2014, pp. 584–589.
[20] Kurilshikov, A. et al. "Large-scale association analyses identify host factors influencing human gut microbiome composition." Nat Genet, vol. 53, no. 2, 2021, pp. 156–165.
[21] Moitinho-Silva, L. et al. "Host genetic factors related to innate immunity, environmental sensing and cellular functions are associated with human skin microbiota." Nat Commun, vol. 13, no. 1, 2022, p. 6271.
[22] Aulchenko, YS, et al. "Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts." Nat Genet, vol. 41, no. 1, 2009, pp. 47-55. PMID: 19060911.